Learn more

NANJING KAEDI BIOTECH INC

Overview
  • Total Patents
    14
  • GoodIP Patent Rank
    123,248
  • Filing trend
    ⇩ 25.0%
About

NANJING KAEDI BIOTECH INC has a total of 14 patent applications. It decreased the IP activity by 25.0%. Its first patent ever was published in 2016. It filed its patents most often in China, WIPO (World Intellectual Property Organization) and United States. Its main competitors in its focus markets pharmaceuticals, biotechnology and measurement are GLUCKSMANN MARIA ALEXANDRA, VIROGIN BIOTECH CANADA LTD and AKSHAYA BIO INC.

Patent filings in countries

World map showing NANJING KAEDI BIOTECH INCs patent filings in countries

Patent filings per year

Chart showing NANJING KAEDI BIOTECH INCs patent filings per year from 1900 to 2020

Top inventors

# Name Total Patents
#1 Dai Hongjiu 14
#2 Zhao Xudong 8
#3 Sun Bin 5
#4 Xu Hui 5
#5 Xiong Bo 5
#6 Zhu Liangjing 5
#7 Li Xiaoliang 4
#8 Zhang Zheng 4
#9 Zhou Jie 3
#10 Wang Mengyao 2

Latest patents

Publication Filing date Title
CN112159475A Siglec-15 monoclonal antibody and application thereof
CN112142854A Immune regulation specific chimeric antigen receptor cell and preparation method and application thereof
CN111978412A Armed targeting TGF-beta specific chimeric antigen receptor cell and preparation method and application thereof
CN111607006A Specific chimeric antigen receptor cell armed with CXCR 2-targeting ligand and preparation method and application thereof
CN111675765A Armed chimeric antigen receptor cell of targeted coronavirus SPIKE, preparation method and application
WO2019061012A1 Preparation of chimeric antigen receptor t-cell specifically targeting cd47 and application thereof
WO2018165913A1 Specific chimeric antigen receptor targeting nkg2dl and car-t cell thereof and use thereof
WO2018040537A1 Preparation method for cldn18.2 specific chimeric antigen receptor t-cell with human pd-1 gene knockout and use thereof
CN106480097A Knocking out that people PD 1 is gene constructed using CRISPR/Cas9 technology can the method for targeting MSLN novel C AR T cell and its application